Treatment of gliomas using organonitro compound combination therapy
US11701351B2 · kind B2 · utility
2Cited by
39References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 6, 2021 |
| Grant date | Jul 18, 2023 |
| Priority date | — |
| Expiry date | Apr 6, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N5/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.